

Saskatoon Health Region ANTIBIOGRAM 2016
Pediatric Patients - INPATIENTS - All Isolates
January 1, 2016 - December 31, 2016

Inpatients – % Susceptible

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin ³	Tobramycin	Vancomycin
GRAM-NEGATIVE BACTERIA																										
<i>Escherichia coli</i> ¹	95			47		84	98	72	94		81		82	100	100					93		74	99	89	91	
<i>Enterobacter cloacae</i> ²	32			R		R	53	R	R		53		53	100	78					100		97	34	100	100	
<i>Haemophilus influenzae</i> †	12			50						75	100						100				100	50				
<i>Klebsiella pneumoniae</i> ¹	30			R		93	93	90	97		97		97	100	100					90		93	60	93	93	
<i>Klebsiella oxytoca</i> †	17			R		94	88	59	100		100		100	100	100					100		94	94	100	100	
<i>Pseudomonas aeruginosa</i> ²	41						83						76	73						81				76	83	

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Nitrofurantoin (urine only)	Gentamicin ³	Tobramycin	Vancomycin
GRAM-POSITIVE BACTERIA																										
<i>Staphylococcus aureus</i> , all																										
- methicillin-susceptible (MSSA)	88				100											76		68	92	93	93	93		93	100	
- methicillin-resistant (MRSA)	59	R	R	R	R	R	R	R	R	R	R	R	R	R	R	80		66	98	90	90	100		100	100	
<i>Staphylococcus epidermidis</i> †	25			R												40		R	100	64	64	68		84		
<i>Streptococcus pneumoniae</i> †	12	100	83							92	100	100				90		83			100				100	
<i>Enterococcus faecalis</i> , all	60			100				R	R	R	R	R						R	R	91	97		100		100	

R - intrinsically resistant or less than 25% empiric susceptibility

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

¹ 3.2 % of *E.coli* (n=3) and 3.3 % of *K.pneumoniae* (n=1) were +ESBL (extended spectrum beta-lactamase)

² these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

³ susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only